Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.

Clayton AH, Lucas J, DeRogatis LR, Jordan R.

Clin Ther. 2017 Mar;39(3):514-526.e14. doi: 10.1016/j.clinthera.2017.01.018. Epub 2017 Feb 9.

2.

Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.

White WB, Myers MG, Jordan R, Lucas J.

J Hypertens. 2017 Apr;35(4):761-768. doi: 10.1097/HJH.0000000000001221.

3.

Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.

Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ.

Womens Health (Lond). 2016 Jun;12(3):325-37. doi: 10.2217/whe-2016-0018. Epub 2016 May 16.

4.

Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.

Safarinejad MR, Hosseini SY.

J Urol. 2008 Mar;179(3):1066-71. doi: 10.1016/j.juro.2007.10.063. Epub 2008 Jan 18.

PMID:
18206919
6.

An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.

Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R.

J Sex Med. 2006 Jul;3(4):628-638. doi: 10.1111/j.1743-6109.2006.00268.x.

PMID:
16839319
10.

PT-141: a melanocortin agonist for the treatment of sexual dysfunction.

Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY.

Ann N Y Acad Sci. 2003 Jun;994:96-102.

PMID:
12851303

Supplemental Content

Loading ...
Support Center